Abstract Number: 2173 • ACR Convergence 2023
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…Abstract Number: 1042 • ACR Convergence 2023
B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…Abstract Number: 0363 • ACR Convergence 2023
Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort
Background/Purpose: Refractory systemic juvenile idiopathic arthritis (sJIA) in children can be complicated by repeated episodes of macrophage activation syndrome (MAS) or sJIA-related lung disease (sJIA-LD).…Abstract Number: 0662 • ACR Convergence 2023
Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis
Background/Purpose: The treatment armamentarium with immunosuppressive treatments (ISTs) for interstitial lung disease (ILD) in systemic sclerosis (SSc) has greatly expanded. It is to date unclear…Abstract Number: 1050 • ACR Convergence 2023
Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols
Background/Purpose: Lung ultrasound (LUS) has proven useful to detect interstitial lung disease (ILD) among patients with SSc when compared to high-resolution computerized tomography (HRCT) as…Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…Abstract Number: 1774 • ACR Convergence 2023
Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it's severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation…Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…Abstract Number: 0393 • ACR Convergence 2023
Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement
Background/Purpose: Seropositive and ACPA positive Rheumatoid Arthritis (RA) is associated with significant cardiovascular and pulmonary comorbidity. However, screening for early detection of pulmonary involvement especially…Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 39
- Next Page »